Sigma Planning Corp Sells 1,654 Shares of Johnson & Johnson (NYSE:JNJ)

Sigma Planning Corp decreased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,375 shares of the company’s stock after selling 1,654 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Sigma Planning Corp’s portfolio, making the stock its 17th biggest holding. Sigma Planning Corp’s holdings in Johnson & Johnson were worth $19,238,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EP Wealth Advisors LLC raised its holdings in Johnson & Johnson by 2.8% during the 2nd quarter. EP Wealth Advisors LLC now owns 352,419 shares of the company’s stock valued at $62,558,000 after acquiring an additional 9,578 shares during the period. Choreo LLC raised its holdings in Johnson & Johnson by 1.0% during the 2nd quarter. Choreo LLC now owns 10,500 shares of the company’s stock valued at $1,864,000 after acquiring an additional 108 shares during the period. GHP Investment Advisors Inc. increased its holdings in shares of Johnson & Johnson by 5.7% in the second quarter. GHP Investment Advisors Inc. now owns 43,813 shares of the company’s stock worth $7,777,000 after purchasing an additional 2,367 shares during the period. Compagnie Lombard Odier SCmA increased its holdings in shares of Johnson & Johnson by 2.9% in the second quarter. Compagnie Lombard Odier SCmA now owns 72,935 shares of the company’s stock worth $12,948,000 after purchasing an additional 2,032 shares during the period. Finally, Zullo Investment Group Inc. increased its holdings in shares of Johnson & Johnson by 1.8% in the second quarter. Zullo Investment Group Inc. now owns 16,491 shares of the company’s stock worth $2,927,000 after purchasing an additional 285 shares during the period. Institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $177.01 on Thursday. The company has a 50-day simple moving average of $168.35 and a two-hundred day simple moving average of $171.28. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The firm has a market cap of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the firm earned $2.60 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson announced that its Board of Directors has approved a stock buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s payout ratio is presently 62.95%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now directly owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders have sold 212,646 shares of company stock valued at $36,791,022 over the last ninety days. 0.35% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on JNJ shares. Barclays started coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target on the stock. Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Finally, Sanford C. Bernstein cut their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.